Royal College of Surgeons in Ireland - Medical University of Bahrain
Clinical Trials
10
Active:1
Completed:7
Trial Phases
2 Phases
Phase 2:2
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (66.7%)Phase 2
2 (33.3%)Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
Active, not recruiting
- Conditions
- MASLDT2DM (Type 2 Diabetes Mellitus)Non-alcoholic Fatty Liver Disease (NAFLD)Obesity
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Target Recruit Count
- 163
- Registration Number
- NCT07172997
- Locations
- 🇧🇭
Alhakeem Radiology Center, Manama, Manama, Bahrain
🇧🇭King Hamad University Hospital, Al Muharraq, Muharraq, Bahrain
Hypoglycemia Biomarkers to Predict Timing of a Hypoglycemic Event
Completed
- Conditions
- Hypoglycemia
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 150
- Registration Number
- NCT06652867
- Locations
- 🇧🇭
Royal College of Surgeons in Ireland, Manama, Bahrain
Movement Behaviours Among Bahraini Diabetics
Recruiting
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2025-02-26
- Target Recruit Count
- 340
- Registration Number
- NCT06069258
- Locations
- 🇧🇭
Isa Town Health Centre, Building 10, Road 43, Capital Governorate, Bahrain
🇧🇭Ahmed Ali Kanoo Health Centre, Building 2009, Road 2641, Capital Governorate, Bahrain
🇧🇭Halat Bu Maher Health Centre, Building 2858, Road 1653, Muharraq Governorate, Bahrain
Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
Completed
- Conditions
- Covid19SARS-CoV 2 Infection
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 305
- Registration Number
- NCT04993560
- Locations
- 🇧🇭
Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19
Not Applicable
Withdrawn
- Conditions
- Covid19SARS-COV 2
- Prev
- 1
- 2
- Next
News
No news found